초록 ▼

Solutions and aerosols of metal-containing compounds are disclosed. Methods of preparing and using the solutions and aerosols, particularly in the treatment of a subject having a condition, are also disclosed. The metal-containing material can be, for example, an antimicrobial material, an antibacte

Solutions and aerosols of metal-containing compounds are disclosed. Methods of preparing and using the solutions and aerosols, particularly in the treatment of a subject having a condition, are also disclosed. The metal-containing material can be, for example, an antimicrobial material, an antibacterial material, an anti-inflammatory material, an anti-fungal material, an anti-viral material, an anti-cancer material, a pro-apoptosis material, and/or an MMP modulating material. In certain embodiments, the metal-containing material is an atomically disordered, silver-containing material.

대표청구항 ▼

What is claimed is: 1. A pharmaceutical composition, comprising: a pharmaceutically acceptable carrier selected from the group consisting of DMSO and liposomes; and a silver-containing compound in the pharmaceutically acceptable carrier; wherein: the pharmaceutical composition comprises from about

What is claimed is: 1. A pharmaceutical composition, comprising: a pharmaceutically acceptable carrier selected from the group consisting of DMSO and liposomes; and a silver-containing compound in the pharmaceutically acceptable carrier; wherein: the pharmaceutical composition comprises from about 0.01 weight percent to about 5 weight percent of the silver-containing compound; when said pharmaceutically acceptable carrier is DMSO, DMSO is present in an amount sufficient to assist in the penetration of skin and the silver-containing compound is selected from the group consisting of nanocrystalline silver-containing compounds and atomically disordered silver-containing compounds; and when said pharmaceutically acceptable carrier is a liposome, the silver-containing compound is selected from the group consisting of atomically disordered silver-containing compounds. 2. The pharmaceutical composition of claim 1, wherein the pharmaceutical composition comprises at least about 0.1 weight percent of the silver-containing compound. 3. The pharmaceutical composition of claim 1, wherein the pharmaceutical composition comprises at least about 0.5 weight percent of the silver-containing compound. 4. The pharmaceutical composition of claim 1, wherein the pharmaceutical composition comprises at least about 0.75 weight percent of the silver-containing compound. 5. The pharmaceutical composition of claim 1, wherein the pharmaceutical composition comprises at least about one weight percent of the silver-containing compound. 6. The pharmaceutical composition of claim 1, wherein the pharmaceutical composition comprises at least about two weight percent of the silver-containing compound. 7. The pharmaceutical composition of claim 1, wherein the silver-containing compound is selected from the group consisting of atomically disordered silver oxides, silver nitrides, silver borides, silver halides and silver hydrides. 8. The pharmaceutical composition of claim 1, wherein the silver-containing compound is selected from the group consisting of atomically disordered silver oxides. 9. The pharmaceutical composition of claim 1, wherein the pharmaceutically acceptable carrier is DMSO and the silver-containing compound is selected from the group consisting of nanocrystalline silver oxides, silver nitrides, silver borides, silver halides and silver hydrides. 10. The pharmaceutical composition of claim 1, wherein the pharmaceutically acceptable carrier is DMSO and the silver-containing compound is selected from the group consisting of nanocrystalline silver oxides. 11. The pharmaceutical composition of claim 1, wherein the silver-containing compound is nanocrystalline silver and the pharmaceutically acceptable carrier is DMSO. 12. The pharmaceutical composition of claim 1, wherein the silver-containing compound is a nanocrystalline silver oxide and the pharmaceutically acceptable carrier is DMSO. 13. The pharmaceutical composition of claim 1, wherein the silver-containing compound is atomically disordered silver. 14. The pharmaceutical composition of claim 1, wherein the pharmaceutically acceptable carrier is a liposome. 15. The pharmaceutical composition of claim 1, wherein the pharmaceutical composition is in the form of a sustained release article. 16. The pharmaceutical composition of claim 1, wherein the pharmaceutically acceptable carrier is DMSO and the silver-containing compound present in the composition is at least about 0.1 weight percent nanocrystalline silver. 17. The pharmaceutical composition of claim 16, wherein the silver-containing compound present in the composition is at least about 0. 5 weight percent. 18. The pharmaceutical composition of claim 16, wherein the silver-containing compound present in the composition is at least about 0. 75 weight percent. 19. The pharmaceutical composition of claim 16, wherein the silver-containing compound present in the composition is at least about 1 weight percent. 20. The pharmaceutical composition of claim 16, wherein the silver-containing compound present in the composition is at least about 2 weight percent. 21. The pharmaceutical composition of claim 1, wherein the silver-containing compound present in the composition is at least about 0. 1 weight percent atomically disordered silver. 22. The pharmaceutical composition of claim 21, wherein the silver-containing compound present in the composition is at least about 0. 5 weight percent. 23. The pharmaceutical composition of claim 21, wherein the silver-containing compound present in the composition is at least about 0. 75 weight percent. 24. The pharmaceutical composition of claim 21, wherein the silver-containing compound present in the composition is at least about 1 weight percent. 25. The pharmaceutical composition of claim 21, wherein the silver-containing compound present in the composition is at least about 2 weight percent. 26. The pharmaceutical composition of claim 1, wherein the silver-containing compound present in the composition is at least about 0. 1 weight percent atomically disordered silver oxide. 27. The pharmaceutical composition of claim 26, wherein the silver-containing compound present in the composition is at least about 0. 5 weight percent. 28. The pharmaceutical composition of claim 26, wherein the silver-containing compound present in the composition is at least about 0. 75 weight percent. 29. The pharmaceutical composition of claim 26, wherein the silver-containing compound present in the composition is at least about 1 weight percent. 30. The pharmaceutical composition of claim 26, wherein the silver-containing compound present in the composition is at least about 2 weight percent. 31. The pharmaceutical composition of claim 1, wherein the pharmaceutically acceptable carrier is DMSO and the silver-containing compound present in the composition is at least about 0.1 weight percent of a nanocrystalline silver oxide. 32. The pharmaceutical composition of claim 31, wherein the silver-containing compound present in the composition is at least about 0. 5 weight percent. 33. The pharmaceutical composition of claim 31, wherein the silver-containing compound present in the composition is at least about 0. 75 weight percent. 34. The pharmaceutical composition of claim 31, wherein the silver-containing compound present in the composition is at least about 1 weight percent. 35. The pharmaceutical composition of claim 31, wherein the silver-containing compound present in the composition is at least about 2 weight percent. 36. The pharmaceutical composition of claim 1, wherein the pharmaceutically acceptable carrier is DMSO and the silver-containing compound present in the composition is at least about 0.1 weight percent of a nanocrystalline silver compound. 37. The pharmaceutical composition of claim 36, wherein the silver-containing compound present in the composition is at least about 0. 5 weight percent. 38. The pharmaceutical composition of claim 36, wherein the silver-containing compound present in the composition is at least about 0. 75 weight percent. 39. The pharmaceutical composition of claim 36, wherein the silver-containing compound present in the composition is at least about 1 weight percent. 40. The pharmaceutical composition of claim 36, wherein the silver-containing compound present in the composition is at least about 2 weight percent. 41. The pharmaceutical composition of claim 1, wherein the silver-containing compound present in the composition is at least about 0. 1 weight percent of an atomically disordered silver compound. 42. The pharmaceutical composition of claim 41, wherein the silver-containing compound present in the composition is at least about 0. 5 weight percent. 43. The pharmaceutical composition of claim 41, wherein the silver-containing compound present in the composition is at least about 0. 75 weight percent. 44. The pharmaceutical composition of claim 41, wherein the silver-containing compound present in the composition is at least about 1 weight percent. 45. The pharmaceutical composition of claim 41, wherein the silver-containing compound present in the composition is at least about 2 weight percent.